Les Pèlerins de Torus - Contributions [fr]

Ergotamine: A Historical And Pharmacological Overview

2026-07-16T19:34:46Z

AracelyPamphlett : Page créée avec «  Ergotamine is a naturally occurring alkaloid derived from the ergot fungus, Claviceps purpurea, which infects rye and other grains. Its history is intertwined with both medicinal use and notorious outbreaks of ergotism, a condition caused by ergot alkaloid poisoning. Isolated in the early 20th century, ergotamine became a cornerstone in the acute treatment of migraine headaches. This report provides a brief overview of ergotamine's chemistry, pharmacology, th... »

Ergotamine is a naturally occurring alkaloid derived from the ergot fungus, Claviceps purpurea, which infects rye and other grains. Its history is intertwined with both medicinal use and notorious outbreaks of ergotism, a condition caused by ergot alkaloid poisoning. Isolated in the early 20th century, ergotamine became a cornerstone in the acute treatment of migraine headaches. This report provides a brief overview of ergotamine's chemistry, pharmacology, therapeutic applications, adverse effects, and its role in contemporary medicine. Historical Context Ergot has been known since ancient times. In the Middle Ages, ergot-contaminated rye caused epidemics of ergotism (St. Anthony's fire), characterized by gangrene, convulsions, and hallucinations. The medical utility of ergot was recognized for inducing uterine contractions in obstetrics. In 1918, the Swiss chemist Arthur Stoll isolated ergotamine, the first pure ergot alkaloid. Its vasoconstrictive properties led to its use in migraine management, which became widespread by the 1930s. Chemistry and Pharmacology Ergotamine belongs to the ergopeptine class of ergot alkaloids. Its structure consists of a tetracyclic ergoline ring system with a peptide side chain. It acts as a partial agonist at various serotonin (5-HT) receptors, particularly 5-HT1B and 5-HT1D, as well as at alpha-adrenergic and dopamine receptors. The antimigraine effect is primarily attributed to vasoconstriction of dilated cranial blood vessels via 5-HT1B receptors and inhibition of trigeminal nerve neuropeptide release via 5-HT1D receptors. Ergotamine also exhibits uterine [https://www.buzzfeed.com/search?q=stimulant stimulant] effects. Therapeutic Uses Ergotamine's main indication is the acute treatment of migraine headaches, especially those with aura. It is most effective when administered early in an attack. Formulations include oral tablets, sublingual tablets, rectal suppositories, and injectable solutions. It is often combined with caffeine (e.g., Cafergot) to enhance absorption and efficacy. Ergotamine is not recommended for cluster headaches due to slower onset, though it may be used in some cases. Its use has declined with the advent of triptans (e.g., sumatriptan), which offer better tolerability and selectivity. Dosage and Administration Typical oral doses range from 1 to 2 mg at onset, repeated every 30 minutes if needed, with a maximum of 6 mg per day or 10 mg per week. Rectal suppositories (2 mg) are preferred for patients with nausea. Subcutaneous or intramuscular injection (0.5–1 mg) provides rapid relief. Due to significant variability in response, dosing must be individualized. Adverse Effects and Toxicity Common side effects include nausea, vomiting, muscle cramps, 25mg ([http://pharmaciegorassini.fr http://pharmaciegorassini.fr]) paresthesia, and localized edema. More serious effects arise from vasoconstriction: ergotism can progress to severe peripheral vasospasm, leading to ischemia, gangrene, and necrosis, especially in extremities. Chronic use or overdose may cause ergotamine-induced headache (medication-overuse headache), dependence, and withdrawal symptoms. Contraindications include peripheral vascular disease, coronary artery disease, hypertension, hepatic or renal impairment, sepsis, and pregnancy (due to uterine stimulation and potential teratogenicity). Ergotamine interacts with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, protease inhibitors) increasing toxicity risk. Ergotism Ergotism from medicinal ergotamine is rare today but can occur with misuse or overdose. Symptoms include cold, pale extremities, diminished pulses, claudication, and neurological disturbances such as confusion or seizures. Treatment involves discontinuation of the drug, vasodilators (e.g., nitroprusside, nifedipine), and supportive care. Preventive measures include adhering to dosage limits and avoiding combination with contraindicated drugs. Current Status and Comparison with Triptans [https://www.medcheck-up.com/?s=Ergotamine Ergotamine] remains a second-line option for migraine due to its narrow therapeutic index and lower selectivity compared to triptans. Triptans (5-HT1B/1D agonists) are more specific, have fewer vascular adverse effects, and are better tolerated. However, ergotamine may still be useful in patients who do not respond to triptans or cannot tolerate them, and in settings where cost is a major consideration. Its vasoconstrictive profile contraindicates use in patients with cardiovascular risk factors. Ergotamine is also available as dihydroergotamine (DHE), a derivative with similar properties but improved pharmacokinetics (lower emetic potential, longer half-life) and is administered intranasally or parenterally. Research and Future Directions Recent studies explore ergotamine's potential in other conditions, such as orthostatic hypotension (due to its vasoconstrictor effect) and cluster headache prophylaxis, though evidence is limited. Novel formulations (e.g., pulmonary delivery) aim to improve onset and reduce gastrointestinal side effects. Understanding of ergotamine's receptor pharmacology continues to inform design of new antimigraine agents with fewer off-target effects. Conclusion Ergotamine exemplifies a natural product that transitioned from a medieval poison to a therapeutic agent. Its role in migraine management has diminished but not entirely disappeared, especially in resource-limited settings or for refractory patients. The key to its use lies in careful patient selection, strict dosing limits, and awareness of its potential for serious vasospastic toxicity. As migraine pharmacotherapy evolves, ergotamine's legacy persists, reminding us of the fine line between remedy and risk in medicinal chemistry. In summary, ergotamine remains a valuable but risky tool in the neurologist's armamentarium. Its history is a cautionary tale about drug safety, and its pharmacology continues to inform the development of safer alternatives. With appropriate precautions, ergotamine can still provide relief for selected migraine sufferers worldwide.

Xalatan (Latanoprost): A Comprehensive Report

2026-07-16T18:52:10Z

AracelyPamphlett : Page créée avec «  Xalatan, the brand name for latanoprost, is a prostaglandin F2α analogue developed by Pfizer and approved for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Since its introduction in the late 1990s, Xalatan has become one of the most widely prescribed first-line therapies for glaucoma worldwide due to its efficacy, convenient once-daily dosing, and favorable systemic safety profile. <b... »

Xalatan, the brand name for latanoprost, is a prostaglandin F2α analogue developed by Pfizer and approved for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Since its introduction in the late 1990s, Xalatan has become one of the most widely prescribed first-line therapies for glaucoma worldwide due to its efficacy, convenient once-daily dosing, and favorable systemic safety profile. Mechanism of Action Latanoprost is a prodrug that is hydrolyzed by esterases in the cornea to its active free acid form. It selectively binds to FP prostanoid receptors in the ciliary muscle of the eye. This [https://www.dailymail.co.uk/home/search.html?sel=site&searchPhrase=binding%20increases binding increases] uveoscleral outflow of aqueous humor, thereby reducing IOP. Unlike earlier glaucoma therapies that primarily decrease aqueous production, latanoprost enhances natural drainage pathways, making it particularly effective in lowering IOP by 25–35% from baseline. Pharmacokinetics After topical instillation, latanoprost is rapidly absorbed. Peak IOP reduction occurs approximately 8–12 hours after administration, and the effect can persist for over 24 hours, supporting once-daily dosing. Systemic absorption is minimal and does not produce clinically significant cardiovascular or pulmonary effects, unlike beta-blockers. The drug is metabolized primarily in the liver via fatty acid oxidation, and its metabolites are excreted renally. Clinical Efficacy Multiple large-scale randomized controlled trials have demonstrated the superior IOP-lowering efficacy of latanoprost compared to timolol, the historical gold standard. In the pivotal Phase III studies, latanoprost reduced diurnal IOP by 22–34%, while timolol (0.5% twice daily) achieved 18–25% reduction. Latanoprost also provides more consistent IOP control over 24 hours, particularly during the nocturnal period when IOP often peaks. A meta-analysis of 27 trials concluded that latanoprost reduces mean [https://search.un.org/results.php?query=diurnal%20IOP diurnal IOP] by approximately 7–8 mmHg from a baseline of 25 mmHg, with an additional 1–2 mmHg reduction when combined with other agents such as timolol or carbonic anhydrase inhibitors. Fixed-dose combinations like latanoprost-timolol are available for patients requiring even greater lowering. Indications and Usage Xalatan is indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. It is also used off-label for certain types of secondary glaucomas, though its efficacy varies. The recommended dosage is one drop in the affected eye(s) once daily in the evening, as nighttime administration may optimize outflow enhancement. Safety and Tolerability The most notable side effect is conjunctival hyperemia (redness), which occurs in up to 30% of patients but is usually mild and self-limiting. Other common ocular adverse effects include eyelash changes (darkening, thickening, and lengthening), iris pigmentation (particularly in patients with mixed-colored irides), periorbital skin darkening, and a risk of macular edema in pseudophakic patients. Systemic side effects are rare; however, there have been reports of respiratory reactions in asthmatic patients. Long-term use can lead to gradual iris color change, especially in green-blue or hazel eyes, due to increased melanin production. This effect is cosmetic and not associated with pathological changes, but it is permanent and should be discussed with patients. Contraindications and Precautions Xalatan is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation. Caution is advised in patients with Cialis Super Active 20mg ([https://francescobarletta.it/prodotti/cialis-super-active/ francescobarletta.it]) intraocular inflammation (e.g., iritis, uveitis) and in those with a history of macular edema, as prostaglandin analogues may exacerbate these conditions. The preservative benzalkonium chloride in Xalatan eye drops can cause punctate keratopathy and contact lens discoloration; soft contact lenses should be removed before instillation and replaced after 15 minutes. Drug Interactions Formal drug interaction studies are limited, but concurrent use of other prostaglandin analogues should be avoided as they may result in additive side effects without greater efficacy. No significant interactions with systemic medications have been reported. Comparison with Other Prostaglandin Analogues Latanoprost is the prototype prostaglandin analogue. Newer agents such as bimatoprost, travoprost, and tafluprost have similar mechanisms but differ in potency, side effects, and preservative formulations. Bimatoprost may produce greater IOP reduction in some patients but is associated with higher rates of hyperemia and periorbital changes. Latanoprost remains widely preferred due to its balance of efficacy, tolerability, and cost. Clinical Considerations in Practice Xalatan is often selected as first-line therapy due to its robust IOP lowering and systemic safety. It is particularly valuable in patients who cannot tolerate beta-blockers because of asthma or bradycardia. The once-daily regimen improves adherence compared to multiple daily dosing regimens. However, the common ocular side effects require patient counseling. For patients who develop significant hyperemia or eyelash changes, switching to another prostaglandin or adding a twice-daily beta-blocker may be considered. Conclusion Xalatan (latanoprost) remains a cornerstone of glaucoma management more than two decades after its approval. Its proven efficacy in lowering IOP, favorable safety profile, and convenient dosing have established it as a first-line therapeutic option. Ongoing research continues to explore its long-term neuroprotective potential and its role in combination therapies. For the vast majority of patients with open-angle glaucoma or ocular hypertension, Xalatan offers reliable and sustained intraocular pressure control with minimal systemic risk.

Utilisateur:AracelyPamphlett

2026-07-16T18:51:54Z

AracelyPamphlett : Page créée avec « I'm Rosemarie and I live in a seaside city in northern Austria, Steinerkirchen Am Innbach. I'm 38 and I'm will soon finish my study at Playwriting. Feel free to surf to my web page ... Cialis Super Active 20mg ([https://francescobarletta.it/prodotti/cialis-super-active/ francescobarletta.it]) »

I'm Rosemarie and I live in a seaside city in northern Austria, Steinerkirchen Am Innbach. I'm 38 and I'm will soon finish my study at Playwriting. Feel free to surf to my web page ... Cialis Super Active 20mg ([https://francescobarletta.it/prodotti/cialis-super-active/ francescobarletta.it])